Back

Absence of detectable cardiotoxicity with L-Annamycin despite high cumulative anthracycline exposure

20 June 2026 (08:30 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (2) Cardio-Oncology Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Mr Stuart Waymack

Blacksburg (United States of America)

42 More presentations in this session

Presentation thumbnail
Pre-existing cardiovascular disease at cancer diagnosis: national trends and future projections in england
Mr A. Alshahrani (Riyadh, SA)
Abstract Slides
Presentation thumbnail
Causal analysis of radiation dose to the base of the heart and overall survival in lung cancer using targeted maximum likelihood estimation
Mr B. Jiang (Manchester, GB)
Abstract Slides
Presentation thumbnail
High prevalence of embolic complications among cancer patients with non-bacterial thrombotic endocarditis
Doctor M. Merhi (Berlin, DE)
Abstract Slides
Presentation thumbnail
Cardio-oncology in breast cancer patients: descriptive data from a north african cohort
Doctor M. Elelmi (Tunis, TN) Doctor E. Bennour Ep Rabah (Tunis, TN)
Abstract Slides
Presentation thumbnail
Myeloperoxidase as a novel biomarker for prediction of cardiotoxicity: results from a prospective cohort study
Doctor V. Petrusheva (Pleven, BG)
Abstract Slides

Access the full session

Session thumbnail
Poster session (2)

The Event

Event poster

ESC Cardio-Oncology 2026

20 June 2026 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources